Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

When will more useful predictive factors be ready for use?

Louis Mauriac1, Marc Debled, Gaëtan MacGrogan

  • 1Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France. mauriac@bergonie.org

Breast (Edinburgh, Scotland)
|September 20, 2005
PubMed
Summary

Genomic profiling may help identify patients who can safely avoid adjuvant chemotherapy. This approach aims to personalize treatment, improving outcomes and reducing unnecessary side effects for breast cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF-β1-dependent mechanism.

Cell reports·2026
Same author

Adenoid cystic carcinoma of the breast: a case series of 26 patients.

Breast cancer research and treatment·2026
Same author

Cancer cells transfer invasive properties through microRNAs contained in collagen tracks.

Cell reports·2025
Same author

Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Clinical pharmacology and therapeutics·2025
Same author

[Apocrine lesions of the breast].

Annales de pathologie·2025
Same author

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

NPJ breast cancer·2025

Area of Science:

  • Oncology
  • Genomics
  • Translational Research

Background:

  • Adjuvant chemotherapy is a standard treatment but offers suboptimal performance for some patients.
  • Identifying patients who benefit least or develop resistance is crucial for treatment optimization.
  • Current prognostic factors require enhancement for better patient stratification.

Purpose of the Study:

  • To improve the cost-benefit ratio of adjuvant chemotherapy.
  • To identify prognostic factors for selecting patients who do not need adjuvant treatment.
  • To discover predictive factors for optimizing individual therapeutic strategies.

Main Methods:

  • Utilizing microarray technologies to reveal genetic profiles.
  • Conducting the Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial comparing genomic profiling with clinico-pathologic indices.

Related Experiment Videos

  • Initiating the EORTC 10994 trial to assess neoadjuvant chemotherapy efficacy in p53 mutated tumors.
  • Evaluating gene profiles for predicting p53 status.

    • Main Results:

    • Genomic profiling shows promise in identifying patient subgroups.
    • The MINDACT trial aims to spare women with favorable genomic signatures from adjuvant chemotherapy.
    • The EORTC 10994 trial investigates docetaxel versus anthracyclines for p53 mutated tumors.

    Conclusions:

    • New genomic prognostic factors are under development.
    • Genomic signatures offer a promising avenue for optimizing adjuvant chemotherapy indications.
    • Personalized medicine approaches are key to enhancing chemotherapy effectiveness and patient selection.